



Published in final edited form as:

J Pharm Pharm Sci. ; 11(2): 1s–13s.

Molecular Targets for Diagnostics and Therapeutics of Severe Acute Respiratory Syndrome (SARS-CoV)

Pravin K. Bhatnagar, Dipankar Das, and Mavanur R. Suresh

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada

Abstract

Purpose—The large number of deaths in a short period of time due to the spread of severe acute respiratory syndrome (SARS) infection led to the unparalleled collaborative efforts world wide to determine and characterize the new coronavirus (SARS-CoV). The full genome sequence was determined within weeks of the first outbreak by the Canadian group with international collaboration. As per the World Health Organization (WHO), the continual lack of a rapid laboratory test to aid the early diagnosis of suspected cases of SARS makes this area a priority for future research. To prevent deaths in the future, early diagnosis and therapy of this infectious disease is of paramount importance.

Methods—This review describes the specific molecular targets for diagnostics and therapeutics of viral infection.

Results—The three major diagnostic methods available for SARS includes viral RNA detection by reverse transcription polymerase chain reaction (RT-PCR), virus induced antibodies by immunofluorescence assay (IFA) or by enzyme linked immunosorbant assay (ELISA) of nucleocapsid protein (NP). The spike glycoprotein of SARS-CoV is the major inducer of neutralizing antibodies. The receptor binding domain (RBD) in the S1 region of the spike glycoprotein contains multiple conformational epitopes that induces highly potent neutralizing antibodies. The genetically engineered attenuated form of the virus or viral vector vaccine encoding for the SARS-CoV spike glycoprotein has been shown to elicit protective immunity in vaccinated animals.

Conclusion—NP is the preferred target for routine detection of SARS-CoV infection by ELISA which is an economical method compared to other methods. The RBD of the spike glycoprotein is both a functional domain for cell receptor binding and also a major neutralizing determinant of SARS-CoV. The progress in evaluating a therapeutic or vaccine would depend on the availability of clinically relevant animal model.

Introduction

The outbreak of severe acute respiratory syndrome (SARS) epidemic in 2002-2003 infected over 8000 people globally (in more than 30 countries across 5 continents) and led to the death of over 900 people with a fatality rate of 9.6%. This new emerging disease represented the most recent threat to human health as it has been reported to be highly contagious (1-3). The large number of deaths in a short period of time due to SARS led to the collaborative efforts world wide to determine and characterize the new Coronavirus, the etiological agent of SARS (SARS-CoV). Indirect evidences have suggested that SARS-CoV may have originated from wild animals such as civet cats in southern China, with the isolation of SARS-CoV-like virus from Himalayan palm in a live animal market in Guangdong Province of China (4). There were also reports that horseshoe bats may be a natural reservoir of SARS-CoV (5). The nucleotide

sequence homology between the SARS-CoV-like virus isolated from animals and SARS-CoV isolated from human has been found to be 99% (4). As per the WHO, the continual lack of a rapid laboratory test to aid the diagnosis of suspected cases of SARS makes this area a priority for future research. Thus the development of simple inexpensive screening and diagnostic tests for specific and early detection of SARS-CoV will contribute to the risk management of a future disease outbreak.

Coronaviruses are a group of positive sense, single stranded RNA viruses that infect humans and animals. In a short period of time the SARS-CoV was identified and initial laboratory protocols for diagnosing SARS were disseminated. The need for the early diagnosis of SARS is vital due to the difficulty in clinically diagnosing this infection and its rapid nosocomial transmission.

The current WHO criteria for laboratory confirmation of SARS-CoV is based on either detection of SARS-CoV RNA by PCR, increase in SARS-CoV antibodies in body fluids, or isolation of SARS-CoV from clinical samples. PCR and antibody detection have been the most widely used diagnostic tests for SARS due to the fact that viral culture is time consuming and insensitive. It has also been reported that antibody detection is the most important method during the convalescent phase (6).

SARS-CoV

Three laboratories within the WHO network independently reported the isolation of a novel coronavirus from clinical specimens of patients with SARS (1,2,7). The cell lines like MRC5, Hep-2, RDE and HeLaB95-8 that were used by different laboratories to culture the virus proved unproductive. The virus was however successfully isolated in Vero-E6 cells in two laboratories and from FRhK-4 cells in the third laboratory (8). The identification of the causative agent as a coronavirus was made by electron microscopy of virus infected cells. Much later, the Dutch group confirmed the Koch's postulates by infecting primates with the virus isolates (9). Within weeks of the first isolation of the novel coronavirus associated with SARS, a Canadian group from Michael Smith Genome Science Centre in Vancouver, British Columbia, and National Microbiology Laboratory in Winnipeg, Manitoba, completely sequenced the genome of the virus (10) closely followed by another group from the Center for Disease Control (CDC), Atlanta, USA (11). Like other known coronaviruses, SARS-CoV is an enveloped positive stranded RNA virus, featuring a large viral genome of approximately 30 kb in length with 11 Open Reading Frames (ORF's). Coronaviruses have five major ORF's that encodes the replicase, spike, envelope, membrane and NP (12,13). The replicase gene alone is composed of approximately 21 kb which is larger than the whole genome of picornavirus (14). Similar to other known coronaviruses, SARS-CoV is an enveloped virus containing four structural proteins, namely the small membrane (M), envelope (E) glycoprotein, spike (S) glycoprotein and the NP (15). The virus was detected by RT-PCR and by culture in respiratory tract, gastrointestinal tract, cerebrospinal fluid, faeces and urine (16,17) indicating that SARS-CoV was not confined only to respiratory tract but spread to different sites. In one study, the highest percentage of positive RT-PCR was found in the stool sample (18) whereas another study reported that stool samples may not be useful for early diagnosis due to the absence of viral RNA in the initial days of the illness (16). Other approaches like real time nested RT-PCR strategies were also used to increase the detection rate of SARS (19,20). The sensitivity could be increased by testing serial samples collected from the same patients on different days. Initial diagnostic approaches did not focus on serum samples for detection of antigens or antibodies for the diagnosis of SARS. Subsequently it was shown that the viral RNA was found in 78% of the serum samples during the initial days of illness (21). Serodiagnosis has been reported to be the gold standard for confirmation of a diagnosis of SARS by indirect IFA using virus infected cells or extracts of virus infected cells. Employing recombinant viral nucleoprotein

and spike protein antigen serological tests have also been explored (6,22,23). Three major diagnostic methods are currently developed.

(i) Viral RNA detection using quantitative reverse transcription (RT)-PCR (20,24,25) (ii) Antibody detection using indirect fluorescence assay (26) or (iii) using both recombinant NP and culture extract of SARS-CoV-based ELISA (7,27,28). ELISA based antibody detection tests with recombinant antigens are well known to offer higher specificities and reproducibilities. Such tests are easy to standardize and less labour intensive than antibody detection by indirect IFA and thus avoids the requirement of growing SARS-CoV (28-32).

Nucleocapsid and Membrane Proteins: Role in Diagnostics

Reverse Transcription –Polymerase Chain Reaction (RT-PCR)

RT-PCR has been used widely for the rapid detection of the viral genome in different clinical specimens. Identification of a CoV genome by electron microscopy led to the search for conserved regions of the CoV genome and development of RT-PCR assays for SARS-CoV RNA assays. Early diagnosis of SARS-CoV infection, which involves viral RNA detection by RT-PCR first targeted the polymerase (pol) 1b region of the 5' replicase gene using different formats including one step or two step RT-PCR or real time-PCR assays (2,7,33-35). Other report also described an enhanced RT-PCR that involved target preamplification by using two separate amplifications of a region of the pol 1b gene (19). Another group targeted the Nucleocapsid (nuc) gene which involves one step and two step real-time assays (36). A two step real time TaqMan assay targeting the nuc gene has also been tested for diagnostics (37).

Real time PCR assays have been introduced for rapid detection of SARS-CoV infection that targeted both *pol 1b* and *nuc* gene. It was expected that the detection of nucleocapsid transcripts by RT-PCR should enhance the sensitivity of PCR for SARS diagnosis because its template mRNA is the most abundant subgenomic RNA during infection. However, different studies showed that RT-PCR assays targeting the *nuc* gene have not been more sensitive than *pol* gene assays because the bulk of the viral RNA in a clinical specimen is total genomic RNA and not the pure mRNA. In another approach a two step real time assay that targeted the 3' noncoding region of the SARS-CoV genome was tested with excellent sensitivity but has not been evaluated with SARS patients samples (38).

Culturing of SARS-CoV is a less sensitive and difficult method requiring BSL-3 facility. The RT-PCR and quantitative RT-PCR has been the working standard in this routine diagnosis. Although the main clinical symptom of SARS-CoV infection is severe respiratory tract symptoms, it has been found that the virus also infects other organs. It was reported that SARS patients had diarrhea and virus can be cultured from the feces and urine in addition to the respiratory tract (39). A comprehensive monitoring of the time periods of RT-PCR diagnosis after disease onset in different types of specimens such as tracheal and nasopharyngeal aspirates, throat swabs, nasal swabs and rectal swabs has been studied (40). Their study showed that the peak detection rate for SARS-CoV occurred at 2 weeks after the onset of illness for respiratory specimens, at weeks 2-3 for stool or rectal swab specimens and at week 4 for urine specimens. It is likely that the current RT-PCR is not quite sensitive enough to detect the low concentration of SARS-CoV RNA, although RT-PCR is a reliable alternative approach for the early diagnosis of SARS. However, the detection rate for probable SARS was only 37.5-50%.

Detection of Anti-viral antibodies

The presence of specific antibodies against various viral components has been a classical diagnostic method. However, the limitations of this approach are two fold. Firstly, there is a time lag before antibodies appear in body fluids. Secondly the persistence of the antibodies in serum may not distinguish between the current and past infective states. It has been found that

anti-NP antibodies are detected early and with high specificity during infection (41). These authors used three different assays namely Western blot, ELISA, and IFA, using both native and bacterially produced antigens of the virus to evaluate serum samples obtained from 46 patients of SARS, 40 patients with non-SARS pneumonia and 38 healthy individuals. It was reported that 89% of the SARS patient's sera were found to be positive to NP antigen. All the subjects without SARS had no anti-NP antibodies. In another study, peptide induced polyclonal antibodies against NP were produced in rabbits using 6× His recombinant NP antigen. Western blot analysis and immunofluorescent staining of affinity purified antibodies showed that these antibodies specifically recognized SARS-CoV (42). In an earlier report, a full length and six truncated fragments of the nucleocapsid gene were cloned, expressed and purified as glutathione S-transferase (GST) tagged recombinant proteins. These recombinant proteins were reacted to a panel of SARS-CoV positive and negative sera. A major immunodomain of recombinant SARS-CoV nucleocapsid, a truncated 195-amino acid fragment from the C terminus of the NP (N195) was identified by Western blot that had a strong ability to detect antibodies against SARS. The sensitivity and specificity was reported to be 98.5 and 100%, respectively (43). No cross reactivity was reported between the N195 protein and antibodies against chicken, pig and canine coronaviruses. The Western blot assay could distinguish patients with fever caused by other diseases from that of SARS patients, thus reducing the possibility of false positives.

Detection of Viral antigens

The presence of viral antigens in different body fluids is suggestive of current infection. Like most viruses, the NP of SARS-CoV is the most conserved and an ideal target for diagnostics. The NP is the most predominant virus derived protein throughout the infection, likely because its template mRNA is the most abundant subgenomic RNA. This feature makes it a suitable candidate for raising antibodies for antigen diagnostics. The amino acid homology of SARS-CoV NP with other members of coronaviruses have been reported to vary from 27 to 37% (44,45). This is a phosphoprotein and amino acid residues 397-423 interact with the viral RNA genome to form a helical nucleocapsid (45,46). The biological function of coronavirus NP is thought to be in the replication and transcription of viral RNA and to interfere with the cell cycle events of host cells (47,48). In several other coronaviruses, such as murine and turkey coronaviruses, NP has been reported to be highly immunogenic (49,50). It has been reported that NP accumulates intra-cellularly even before it is packed in the mature virus and is the most abundant virus derived protein throughout the infection. A serum antigen assay could avoid the need for nasal aspirate collection and molecular diagnostic techniques. Detection of circulating antigen has been in use for diagnosis and prognosis of a variety of diseases involving HIV p24, Hepatitis B virus, Hepatitis C virus, viral hemorrhagic fever and Cytomegalovirus (51-57). The detailed analysis in hemorrhagic fever caused by Ebola virus suggested that while RT-PCR assay is extremely useful, it should always be supported in combination with antigen-captured ELISA making the diagnosis more reliable (58).

The SARS-CoV NP antigen capture ELISA was developed using a mixture of three monoclonal antibodies (44) and rabbit polyclonal antibodies for detection. The monoclonal antibodies were of IgG1 type and recognized three different epitopes on NP antigen. The sensitivity of the assay was established to be 50 pg/ml using recombinant NP antigen. The sensitivity of the assay was 84.6% (11 out of 13) of serologically confirmed cases of SARS when samples were obtained between 6 to 10 days of the onset of infection. The specificity of the capture assay was found to be 98.5% in (1253 out of 1,272) healthy individuals. The presence of NP antigen was also detected in the early phase of the disease (3-5 days) in 50% of the patients. Several additional monoclonal antibodies (MAbs) against the NP have also been generated (59). One among these is an IgG1 monoclonal antibody (S-A5D5) that reacts specifically with both recombinant and native NP of SARS-CoV. This MAb was used as detector antibody for detection of NP antigen

whereas anti-Guinea Pig polyclonal antibody used as capture antibody in heterosandwich ELISA format. The sensitivity of the capture assay was found to be 37.5 pg of purified NP protein. No false positives results were observed among the sera tested from 60 healthy individuals. Further more, no cross reactivity was observed when infectious bronchitis virus (IBV) and chicken coronavirus were tested. It has also been reported that SARS-CoV NP could be detected using MAb-based antigen capture ELISA in early acute phase serum samples of patients with SARS (60). All of the sera collected from 1 to 10 days after the onset of the symptoms were positive for NP antigen. Nearly all sera were found positive for the NP antigen between days 3 and 5. However, beyond day 11, NP antigen was not detected in group of samples analyzed. The percentage positivity of sera collected between 11 to 15 and 16 to 20 days after the onset of symptoms showed only 36.4 and 21.1% respectively (44,60). The NP protein was not detected beyond day 19. We have cloned the full length codon optimized NP gene in *E. coli*, expressed and purified as His₆ tagged recombinant protein (61). More recently we have developed a point of care immunoswab assay for detection of SARS-CoV NP antigen using MAb and bispecific MAb (BsMAb). The BsMAb has one arm specific to horseradish peroxidase (HRPO) and the other arm specific to SARS-CoV NP antigen (62). The BsMAb was developed by hybrid-hybridoma technology and purified by a novel dual sequential affinity chromatography method for the detection of NP antigen on immunoswabs (63).

With regard to the other molecular targets, very little information is available on the immune response to the M proteins of SARS-CoV. Some studies have demonstrated that the M proteins of coronaviruses were able to induce antibody response in hosts infected by coronavirus or immunized by attenuated recombinant virus expressing M proteins (64-68) thus making M protein also another target for developing diagnostics and a vaccine candidate. The antigenic site on the M proteins has not been determined as yet in SARS-CoV. Studies using Pepscan analysis identified two immunodominant epitopes on the M proteins at the N-terminus (1-31 amino acids) and C terminal region (residues 132-161) and showed that the N-terminal epitope is more immunogenic in patients infected with SARS but less immunogenic in rabbits than the epitope at the C-terminal (69). Their observations brought out the heterogeneity of SARS-CoV in infection and immunization. It has also been shown that the inactivated SARS-CoV was not only able to induce high titers of antibody response against spike glycoprotein and NP antigen (70-72) but also against N terminal and C terminal antigenic sites of M protein in immunized mice and rabbits (69).

Spike Glycoprotein: Role in Therapeutics

The SARS-CoV spike gene encodes a glycoprotein of approximate 150 kDa containing 1255 amino acids. Spike protein of animal coronaviruses have been reported to be immunogenic and immunization of animals using spike protein based vaccine produced neutralizing antibodies that were able to prevent infection caused by the corresponding pathogen (73,74). Spike glycoprotein of SARS-CoV is made up of two domains, S1 and S2. The S1 is near the N-terminus and the S2 near the C- terminus. The S1 and S2 domains are located at the region of amino acid residues 17-680 and 681-1255, respectively (75). The S1 and S2 domains form the globular head and the stalk of the spike protein (76) and play an important role in specific receptor recognition and subsequent cell fusion. Hence this protein is a major target for neutralizing antibodies. It has also been demonstrated that RBD of the S protein contains a key neutralization determinant which can induce potent neutralizing antibodies that block the replication of SARS-CoV in monkeys (69). The receptor for SARS-CoV has been identified as the ACE-2 (77,78). Many neutralizing antibodies have been reported which are capable of blocking the interaction between the spike glycoprotein and the cellular ACE-2 receptor (79). Hence the ACE-2 binding site of the spike glycoprotein provides an attractive target for the development of a SARS therapeutics as well as a vaccine. The spike glycoprotein may mediate membrane fusion and induce neutralizing antibodies in host, raising the possibility that

antibodies against the SARS-CoV spike glycoprotein may also be a good tool for early detection and neutralization of the virus. A 193 amino acid fragment (residues 318-510) in the S1 region was identified as the receptor binding domain of SARS-CoV (74,80,81). In an other report, it has been shown that the recombinant RBD of SARS-CoV spike glycoprotein induced neutralizing antibodies (82). These findings were further supported by the fact that depletion of RBD specific antibodies reduced serum mediated neutralizing activity. Furthermore, a MAb (2C5) was able to block the binding of the RBD to the functional receptor (ACE-2) on the target cells, suggesting that the RBD of spike proteins is an important neutralization determinant of SARS-CoV (72). In another study S1 domain of the spike protein and three truncated fragments expressed by fusion of GST in a pGEX-6p-1 vector were evaluated for antigenicity and immunogenicity. Western blot results showed the 510-672 fragment of the S1 domain is a linear immunogenic dominant epitope.

Immunization of mice with four overlapping fragments of spike glycoprotein revealed that all four proteins could elicit spike protein specific antisera and showed reactivity to the whole spike glycoprotein expressed by recombinant baculovirus in insect cells (83). The computer based analysis also suggested that amino acid residues 450-650 of spike glycoprotein (S450-650) of SARS is solvent accessible (84). It was also supported by the findings (85) that residues 485-625 of spike glycoprotein of SARS-CoV generated neutralizing antibodies against the virus. This is further supported by the work of another group who identified a major immunodominant domain of SARS-CoV spike protein from the S1 region (441-700 amino acids), designated as protein C (86). This recombinant baculovirus expressed protein reacted with all the SARS patients sera. The spike glycoprotein based IFA based on the protein C showed 100% specificity and sensitivity (87). The anti-spike protein antibodies were detected in 63% of the patients in a study conducted on 46 patients with SARS infection (41). Two chimeric immunodominant genes coding for the proteins of SARS-CoV based on bioinformatics were identified and cloned into plasmid pGEX-6p-1 vector and expressed in *E. coli* (88). The proteins expressed by the two chimeric genes were recognized by the SARS patient sera. MAbs produced against these two peptides specifically recognized expression product of S2 and S5 domains, respectively. The S2 and S5 domains correspond to 447-458 aa and 789-799 aa of SARS-CoV spike glycoprotein respectively. A 15 amino acid segment in the C-terminal (1143-1157) of spike glycoprotein has been shown to induce neutralizing antibodies preventing the SARS-CoV infection in VERO-E6 cells (13).

Anti-SARS-CoV Drug

The metallopeptidase, ACE-2, efficiently binds the S1 domain of the SARS-CoV spike protein and has been reported to be a functional receptor for SARS-CoV. The interruption of virus receptor interaction could be a potential target for therapeutics strategies. The receptor-binding S1 domain of SARS-CoV spike protein is a possible target for new SARS antiviral drugs. It has been suggested that antibodies against ACE-2 and not the inhibitors binding to the active site of ACE-2, may be more useful for the development of therapeutic strategies (89). There are several potential targets for the development of antiviral drugs against SARS-CoV. Strategies include a) the disruption of the binding of the virus to the target cell, b) inhibiting the spike RBD domain or its receptor such as ACE-2, c) cell entry inhibitors or d) inhibitors of replication steps, e) virus assembly disruption and f) targeting viral exit. The main SARS-CoV protease also called the 3C-like protease plays an important role in mediating viral replication and transcription functions through extensive proteolytic processing of two replicase polyproteins, pp1a (486 KDa) and pp1ab (790 KDa). The crystal structure of the main protease M^{PRO} for SARS-CoV (strain 229E) and its inhibitor complex led to the design of anti-SARS drugs (14,90). An irreversible inhibition of SARS-CoV M^{PRO} by aza-peptide epoxide (APE) has been reported (91) suggesting that APE has excellent potential as inhibitors of SARS-CoV M^{PRO} and could lead to additional compounds for anti-SARS therapeutics.

Furthermore, the aza-peptide component of APE binds to the substrate binding regions of M^{PRO} in a substrate like manner with excellent structural and chemical complementarity. The kinetic studies and crystal structure studies have shown that M^{PRO} reacts only with the S,S diastereomer of the APE and not its R,R diastereomer of APE (91).

SARS-CoV Vaccine Development

It has been reported that SARS patients show clinical improvement if they are treated with serum from previously infected patients suggesting that passive immunotherapy could be developed for the treatment of infectious diseases (92). The development of SARS vaccine can be approached using several techniques such as live attenuated vaccine (93,94), whole killed vaccine (95), recombinant subunit vaccines (82), recombinant vectored vaccine (96,97), DNA vaccine (98-101) and epitope based vaccine (102,103).

For SARS-CoV, it has been demonstrated that prior infection provided protective immunity in a mouse model and the passive transfer of neutralizing antibodies to naïve mice also protected them from infection (104). This suggested that neutralizing antibodies have an important role in reducing the viral load or preventing further viral replication. A DNA vaccine encoding for the spike glycoprotein alone was able to induce T cell responses along with the neutralizing antibodies. Such antibodies were able to protect the mice from SARS-CoV (100). These findings suggested that spike glycoprotein is in fact the target for viral neutralization in SARS-CoV infection. Similar findings were also reported by other group of workers (96,105). These reports emphasized the potential for developing peptide based vaccine candidates if the neutralizing epitope on spike protein is identified. In a recent study (106) rabbit polyclonal antibodies against five bacterially expressed fragments of spike glycoprotein covering the entire ectodomain (aa 48-1192) were raised. It was demonstrated that all the antibodies were specific and sensitive to both native and denatured forms of full length spike glycoprotein. It was further reported that the anti-SΔ10 antibody which was targeted to amino acid residues 1029-1192 has strong neutralizing activities. This led to the conclusion that this region of spike glycoprotein carries neutralizing epitopes. A high level expression of S1 domain of SARS-CoV in tomato and tobacco has recently been reported (107). This plant derived peptide induces immune responses in mice and showed increased level of SARS-CoV specific IgA and IgG respectively. Other workers (13,72,108) have also identified the regions in the spike glycoproteins responsible for inducing the neutralizing antibodies. These observations confirm that there is a major neutralizing determinant exposed *in vivo* for generating high levels of neutralizing antibodies which blocks the interaction between the spike glycoprotein of SARS-CoV and the cellular receptor ACE-2. In a novel study, the neutralization and viral entry determinants were characterized by deleting a positively charged region, SΔ (422-463) in the RBD of spike glycoprotein (79). The deletion resulted in loss of the ability to induce potent neutralizing antibody and reported that a single positively charged amino acid (R441A) in the spike glycoprotein is an indispensable component for determining the immunogenicity of SARS-CoV major neutralizing domain. The substitution of another amino acid (R453A) abolished the viral entry. Their findings provided evidence indicating that determinants for immunogenicity and viral entry might not be the same. In summary, spike glycoprotein of SARS-CoV is the major inducer of neutralizing antibodies and the RBD in the S1 domain of spike glycoprotein contains multiple conformational neutralizing epitopes that induces highly potent neutralizing antibodies against SARS-CoV (70,72,109,110). The recombinant proteins containing the RBD and vector encoding the RBD sequence can be used to develop a safe vaccine (111). Human MAb to the spike glycoprotein of the SARS-CoV have been developed by various groups. These antibodies were able to neutralize the virus in tissue culture and an animal model and thus may have potential for prevention and treatment (112). The first vaccine tested in clinical trials was made from inactivated form of SARS-CoV. However, this traditional approach to generate polyclonal antibodies to SARS-CoV has presented difficulties

for several reasons including safety concerns in handling SARS particles (3,95). The attenuated form of virus, genetically engineered or vector vaccine encoding for the SARS-CoV spike glycoprotein have shown promising effectiveness in eliciting protective immunity in vaccinated animals. A candidate vaccine has been attempted using three adenoviral-based vectors that expressed SARS-CoV structural antigens including the S1 fragment of spike glycoprotein, the membrane protein and the NP (113). Immunization of rhesus monkeys induced antibody responses against the S1 spike glycoprotein and T cell responses against the NP. In another study, immunization of mice by DNA vaccination with NP, M and E gene induced SARS specific antibodies, T cell proliferation, CTL responses with a pronounced Th1 type of response against NP (114). Two different SARS vaccines, a whole killed SARS-CoV (WKV) and a combination of two adenovirus-based vectors-one expressing the NP and the other expressing the spike (S) protein (Ad S/N), were evaluated for the induction of neutralizing antibodies and their ability to protect against SARS-CoV challenge in a murine model of infection (115). The WKV vaccine given subcutaneously to 129S6/SvEv mice was more effective than Ad S/N given intranasally or intramuscularly in inhibiting SARS-CoV replication in murine respiratory tract. Among the vaccine groups, SARS-CoV specific IgA was found only in sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection. The sera of vaccinated mice contained antibodies to S protein, suggesting a role of this protein in conferring protective immunity against SARS-CoV infection. Current knowledge of the potency of inactivated SARS-CoV vaccine is limited. This SARS-CoV vaccine induced high levels of antibodies against NP, S and M antigen with neutralizing activity (95,116). Intranasal immunization of inactivated SARS-CoV failed to induce detectable levels of specific IgG and IgA antibodies in sera, IgA antibodies in saliva, lungs and intestine unless given with adjuvants (117). Intranasal vaccination of recombinant adeno-associated virus based RBD (RBD-rAAV) could induce highly potent neutralizing mucosal and systemic antibodies specific to SARS-CoV (118,119).

In conclusion, the RBD of spike glycoprotein is both a functional domain for receptor binding and a major neutralizing determinant of SARS-CoV. All vaccines based on spike glycoprotein seem to induce neutralizing antibody responses and those carrying NP can induce NP specific cell mediated immunity. The success however in evaluating a SARS vaccine would depend on the availability of clinically relevant SARS disease animal model to test the efficacy of the vaccines.

Acknowledgements

This work was supported by a research grant (5U01AI061233-02) from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, USA.

References

1. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet* 2003 Apr 19;361(9366):1319–25. [PubMed: 12711465]
2. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med* 2003 May 15;348(20):1967–76. [PubMed: 12690091]
3. Taylor DR. Obstacles and advances in SARS vaccine development. *Vaccine*. 2005 Sep 24;
4. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. *Science* 2003 Oct 10;302(5643):276–8. [PubMed: 12958366]
5. Wang LF, Shi Z, Zhang S, Field H, Daszak P, Eaton BT. Review of bats and SARS. *Emerg Infect Dis* 2006 Dec;12(12):1834–40. [PubMed: 17326933]

6. Wu HS, Chiu SC, Tseng TC, Lin SF, Lin JH, Hsu YH, et al. Serologic and molecular biologic methods for SARS-associated coronavirus infection, Taiwan. *Emerg Infect Dis* 2004 Feb;10(2):304–10. [PubMed: 15030702]
7. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. *N Engl J Med* 2003 May 15;348(20):1953–66. [PubMed: 12690092]
8. Poon LL, Guan Y, Nicholls JM, Yuen KY, Peiris JS. The aetiology, origins, and diagnosis of severe acute respiratory syndrome. *Lancet Infect Dis* 2004 Nov;4(11):663–71. [PubMed: 15522678]
9. Fouchier RA, Kuiken T, Schutten M, van Amerongen G, van Doornum GJ, van den Hoogen BG, et al. Aetiology: Koch's postulates fulfilled for SARS virus. *Nature* 2003 May 15;423(6937):240. [PubMed: 12748632]
10. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, et al. The Genome sequence of the SARS-associated coronavirus. *Science* 2003 May 30;300(5624):1399–404. [PubMed: 12730501]
11. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. *Science* 2003 May 30;300(5624):1394–9. [PubMed: 12730500]
12. Holmes KV, Enjuanes L. *Virology*. The SARS coronavirus: a postgenomic era. *Science* 2003 May 30;300(5624):1377–8. [PubMed: 12775826]
13. Lai SC, Chong PC, Yeh CT, Liu LS, Jan JT, Chi HY, et al. Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV). *J Biomed Sci* 2005 Aug;19:1–17.
14. Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. *Proc Natl Acad Sci U S A* 2003 Nov 11;100(23):13190–5. [PubMed: 14585926]
15. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. *Nat Med* 2004 Dec;10:S88–97. [PubMed: 15577937]
16. Chan KH, Poon LL, Cheng VC, Guan Y, Hung IF, Kong J, et al. Detection of SARS coronavirus in patients with suspected SARS. *Emerg Infect Dis* 2004 Feb;10(2):294–9. [PubMed: 15030700]
17. Hung EC, Chim SS, Chan PK, Tong YK, Ng EK, Chiu RW, et al. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. *Clin Chem* 2003 Dec;49(12):2108–9. [PubMed: 14633896]
18. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet* 2003 May 24;361(9371):1767–72. [PubMed: 12781535]
19. Lau LT, Fung YW, Wong FP, Lin SS, Wang CR, Li HL, et al. A real-time PCR for SARS-coronavirus incorporating target gene pre-amplification. *Biochem Biophys Res Commun* 2003 Dec 26;312(4):1290–6. [PubMed: 14652014]
20. Jiang SS, Chen TC, Yang JY, Hsiung CA, Su IJ, Liu YL, et al. Sensitive and quantitative detection of severe acute respiratory syndrome coronavirus infection by real-time nested polymerase chain reaction. *Clin Infect Dis* 2004 Jan 15;38(2):293–6. [PubMed: 14699465]
21. Ng EK, Ng PC, Hon KL, Cheng WT, Hung EC, Chan KC, et al. Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome. *Clin Chem* 2003 Dec;49(12):2085–8. [PubMed: 14633884]
22. Ho TY, Wu SL, Cheng SE, Wei YC, Huang SP, Hsiang CY. Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein. *Biochem Biophys Res Commun* 2004 Jan 23;313(4):938–47. [PubMed: 14706633]
23. Wang J, Wen J, Li J, Yin J, Zhu Q, Wang H, et al. Assessment of immunoreactive synthetic peptides from the structural proteins of severe acute respiratory syndrome coronavirus. *Clin Chem* 2003 Dec; 49(12):1989–96. [PubMed: 14633869]
24. Poon LL, Chan KH, Wong OK, Cheung TK, Ng I, Zheng B, et al. Detection of SARS coronavirus in patients with severe acute respiratory syndrome by conventional and real-time quantitative reverse transcription-PCR assays. *Clin Chem* 2004 Jan;50(1):67–72. [PubMed: 14709637]

25. Yam WC, Chan KH, Poon LL, Guan Y, Yuen KY, Seto WH, et al. Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel coronavirus. *J Clin Microbiol* 2003 Oct;41(10):4521–4. [PubMed: 14532176]
26. Chan PK, Ng KC, Chan RC, Lam RK, Chow VC, Hui M, et al. Immunofluorescence assay for serologic diagnosis of SARS. *Emerg Infect Dis* 2004 Mar;10(3):530–2. [PubMed: 15109430]
27. Shi Y, Yi Y, Li P, Kuang T, Li L, Dong M, et al. Diagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen-capturing enzyme-linked immunosorbent assay. *J Clin Microbiol* 2003 Dec;41(12):5781–2. [PubMed: 14662982]
28. Woo PC, Lau SK, Wong BH, Tsoi HW, Fung AM, Chan KH, et al. Detection of specific antibodies to severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia. *J Clin Microbiol* 2004 May;42(5):2306–9. [PubMed: 15131220]
29. Woo PC, Lau SK, Wong BH, Chan KH, Chu CM, Tsoi HW, et al. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. *Clin Diagn Lab Immunol* 2004 Jul;11(4):665–8. [PubMed: 15242938]
30. Woo PC, Chong KT, Leung AS, Wong SS, Lau SK, Yuen KY. AFLMP1 encodes an antigenic cell wall protein in *Aspergillus flavus*. *J Clin Microbiol* 2003 Feb;41(2):845–50. [PubMed: 12574298]
31. Yuen KY, Chan CM, Chan KM, Woo PC, Che XY, Leung AS, et al. Characterization of AFMP1: a novel target for serodiagnosis of aspergillosis. *J Clin Microbiol* 2001 Nov;39(11):3830–7. [PubMed: 11682494]
32. Chan CM, Woo PC, Leung AS, Lau SK, Che XY, Cao L, et al. Detection of antibodies specific to an antigenic cell wall galactomannoprotein for serodiagnosis of *Aspergillus fumigatus* aspergillosis. *J Clin Microbiol* 2002 Jun;40(6):2041–5. [PubMed: 12037061]
33. Poon LL, Wong BW, Chan KH, Leung CS, Yuen KY, Guan Y, et al. A one step quantitative RT-PCR for detection of SARS coronavirus with an internal control for PCR inhibitors. *J Clin Virol* 2004 Jul;30(3):214–7. [PubMed: 15135737]
34. Adachi D, Johnson G, Draker R, Ayers M, Mazzulli T, Talbot PJ, et al. Comprehensive detection and identification of human coronaviruses, including the SARS-associated coronavirus, with a single RT-PCR assay. *J Virol Methods* 2004 Dec 1;122(1):29–36. [PubMed: 15488617]
35. Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, Huang Y, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. *J Virol* 2005 Jan;79(2):884–95. [PubMed: 15613317]
36. Mahony JB, Petrich A, Louie L, Song X, Chong S, Smieja M, et al. Performance and Cost evaluation of one commercial and six in-house conventional and real-time reverse transcription-pcr assays for detection of severe acute respiratory syndrome coronavirus. *J Clin Microbiol* 2004 Apr;42(4):1471–6. [PubMed: 15070991]
37. Bressler AM, Nolte FS. Preclinical evaluation of two real-time, reverse transcription-PCR assays for detection of the severe acute respiratory syndrome coronavirus. *J Clin Microbiol* 2004 Mar;42(3):987–91. [PubMed: 15004042]
38. Houg HS, Norwood D, Ludwig GV, Sun W, Lin M, Vaughn DW. Development and evaluation of an efficient 3'-noncoding region based SARS coronavirus (SARS-CoV) RT-PCR assay for detection of SARS-CoV infections. *J Virol Methods* 2004 Sep 1;120(1):33–40. [PubMed: 15234807]
39. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, et al. Identification of severe acute respiratory syndrome in Canada. *N Engl J Med* 2003 May 15;348(20):1995–2005. [PubMed: 12671061]
40. Chan PK, To WK, Ng KC, Lam RK, Ng TK, Chan RC, et al. Laboratory diagnosis of SARS. *Emerg Infect Dis* 2004 May;10(5):825–31. [PubMed: 15200815]
41. Leung DT, Tam FC, Ma CH, Chan PK, Cheung JL, Niu H, et al. Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. *J Infect Dis* 2004 Jul 15;190(2):379–86. [PubMed: 15216476]
42. Chang MS, Lu YT, Ho ST, Wu CC, Wei TY, Chen CJ, et al. Antibody detection of SARS-CoV spike and nucleocapsid protein. *Biochem Biophys Res Commun* 2004 Feb 20;314(4):931–6. [PubMed: 14751221]

43. He Q, Chong KH, Chng HH, Leung B, Ling AE, Wei T, et al. Development of a Western blot assay for detection of antibodies against coronavirus causing severe acute respiratory syndrome. *Clin Diagn Lab Immunol* 2004 Mar;11(2):417–22. [PubMed: 15013997]
44. Che XY, Qiu LW, Pan YX, Wen K, Hao W, Zhang LY, et al. Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome. *J Clin Microbiol* 2004 Jun;42(6):2629–35. [PubMed: 15184444]
45. Timani KA, Ye L, Zhu Y, Wu Z, Gong Z. Cloning, sequencing, expression, and purification of SARS-associated coronavirus nucleocapsid protein for serodiagnosis of SARS. *J Clin Virol* 2004 Aug;30(4):309–12. [PubMed: 15163419]
46. Surjit M, Liu B, Kumar P, Chow VT, Lal SK. The nucleocapsid protein of the SARS coronavirus is capable of self-association through a C-terminal 209 amino acid interaction domain. *Biochem Biophys Res Commun* 2004 May 14;317(4):1030–6. [PubMed: 15094372]
47. Parker MM, Masters PS. Sequence comparison of the N genes of five strains of the coronavirus mouse hepatitis virus suggests a three domain structure for the nucleocapsid protein. *Virology* 1990 Nov;179(1):463–8. [PubMed: 2171216]
48. Kuo L, Masters PS. Genetic evidence for a structural interaction between the carboxy termini of the membrane and nucleocapsid proteins of mouse hepatitis virus. *J Virol* 2002 May;76(10):4987–99. [PubMed: 11967315]
49. Wage H, Schliephake A, Korner H, Flory E, Wage H. An immunodominant CD4 + T cells site on the nucleocapsid protein of murine coronaviruses contribute to protection against encephalomyelitis. *J Gen Virol* 1993;74:1287–94. [PubMed: 8393072]
50. Akin A, Lin TL, Wu CC, Bryan TA, Hooper T, Schrader D. Nucleocapsid protein gene sequence analysis reveals close genomic relationship between turkey coronavirus and avian infectious bronchitis virus. *Acta Virol* 2001 Feb;45(1):31–8. [PubMed: 11394575]
51. Cano H, Candela MJ, Lozano ML, Vicente V. Application of a new enzyme-linked immunosorbent assay for detection of total hepatitis C virus core antigen in blood donors. *Transfus Med* 2003 Oct;13(5):259–66. [PubMed: 14617336]
52. Clement F, Dewint P, Leroux-Roels G. Evaluation of a new rapid test for the combined detection of hepatitis B virus surface antigen and hepatitis B virus e antigen. *J Clin Microbiol* 2002 Dec;40(12):4603–6. [PubMed: 12454159]
53. Icardi G, Ansaldi F, Bruzzone BM, Durando P, Lee S, de Luigi C, et al. Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen. *J Clin Microbiol* 2001 Sep;39(9):3110–4. [PubMed: 11526137]
54. Mourton C, Romestand B, de Kinkelin P, Jeffroy J, Le Gouvello R, Pau B. Highly sensitive immunoassay for direct diagnosis of viral hemorrhagic septicemia which uses antinucleocapsid monoclonal antibodies. *J Clin Microbiol* 1992 Sep;30(9):2338–45. [PubMed: 1400999]
55. St George K, Boyd MJ, Lipson SM, Ferguson D, Cartmell GF, Falk LH, et al. A multisite trial comparing two cytomegalovirus (CMV) pp65 antigenemia test kits, biotest CMV brite and Bartels/Argene CMV antigenemia. *J Clin Microbiol* 2000 Apr;38(4):1430–3. [PubMed: 10747120]
56. Sutthent R, Gaudart N, Chokpaibulkit K, Tanliang N, Kanoksinsombath C, Chaisilwatana P. p24 Antigen detection assay modified with a booster step for diagnosis and monitoring of human immunodeficiency virus type 1 infection. *J Clin Microbiol* 2003 Mar;41(3):1016–22. [PubMed: 12624024]
57. Weber B, Dengler T, Berger A, Doerr HW, Rabenau H. Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: IMMULITE HBsAg and IMMULITE 2000 HBsAg. *J Clin Microbiol* 2003 Jan;41(1):135–43. [PubMed: 12517838]
58. Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. *J Virol* 2004 Apr;78(8):4330–41. [PubMed: 15047846]
59. He Q, Du Q, Lau S, Manopo I, Lu L, Chan SW, et al. Characterization of monoclonal antibody against SARS coronavirus nucleocapsid antigen and development of an antigen capture ELISA. *J Virol Methods* 2005 Jul;127(1):46–53. [PubMed: 15893565]

60. Di B, Hao W, Gao Y, Wang M, Wang YD, Qiu LW, et al. Monoclonal antibody-based antigen capture enzyme-linked immunosorbent assay reveals high sensitivity of the nucleocapsid protein in acute-phase sera of severe acute respiratory syndrome patients. *Clin Diagn Lab Immunol* 2005 Jan;12(1): 135–40. [PubMed: 15642998]
61. Das D, Suresh MR. Copious production of SARS-CoV nucleocapsid protein employing codon optimized synthetic gene. *J Virol Methods* 2006 Nov;137(2):343–6. [PubMed: 16904198]
62. Kammila S, Das D, Bhatnagar PK, Sunwoo H, Zyas G, King M, et al. A rapid point of care immunoswab assay for SARS-CoV detection. *Journal of Virological Methods*. 2008Submitted
63. Bhatnagar PK, Das D, Suresh MR. Sequential affinity purification of peroxidase tagged bispecific anti-SARS-CoV antibodies on phenylboronic acid agarose. *J Chromatogr B Analyt Technol Biomed Life Sci* 2008 Mar 1;863(2):235–41.
64. Elia G, Fiermonte G, Pratelli A, Martella V, Camero M, Cirone F, et al. Recombinant M protein-based ELISA test for detection of antibodies to canine coronavirus. *J Virol Methods* 2003 May;109(2):139–42. [PubMed: 12711056]
65. Fiscus SA, Teramoto YA. Antigenic comparison of feline coronavirus isolates: evidence for markedly different peplomer glycoproteins. *J Virol* 1987 Aug;61(8):2607–13. [PubMed: 3599183]
66. Han X, Bartlam M, Jin YH, Liu X, He X, Cai X, et al. The expression of SARS-CoV M gene in *P. Pastoris* and the diagnostic utility of the expression product. *J Virol Methods* 2004 Dec 1;122(1): 105–11. [PubMed: 15488627]
67. de Haan CA, Kuo L, Masters PS, Vennema H, Rottier PJ. Coronavirus particle assembly: primary structure requirements of the membrane protein. *J Virol* 1998 Aug;72(8):6838–50. [PubMed: 9658133]
68. Vennema H, de Groot RJ, Harbour DA, Horzinek MC, Spaan WJ. Primary structure of the membrane and nucleocapsid protein genes of feline infectious peritonitis virus and immunogenicity of recombinant vaccinia viruses in kittens. *Virology* 1991 Mar;181(1):327–35. [PubMed: 1847259]
69. He Y, Zhou Y, Siddiqui P, Niu J, Jiang S. Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. *J Clin Microbiol* 2005 Aug;43(8):3718–26. [PubMed: 16081901]
70. He Y, Zhou Y, Siddiqui P, Jiang S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. *Biochem Biophys Res Commun* 2004 Dec 10;325(2):445–52. [PubMed: 15530413]
71. He Y, Zhou Y, Wu H, Kou Z, Liu S, Jiang S. Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus. *J Clin Microbiol* 2004 Nov;42(11):5309–14. [PubMed: 15528730]
72. He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, et al. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. *Virology* 2005 Mar 30;334(1):74–82. [PubMed: 15749124]
73. Gallagher TM, Buchmeier MJ. Coronavirus spike proteins in viral entry and pathogenesis. *Virology* 2001 Jan 20;279(2):371–4. [PubMed: 11162792]
74. Wong SK, Li W, Moore MJ, Choe H, Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. *J Biol Chem* 2004 Jan 30;279(5):3197–201. [PubMed: 14670965]
75. Spiga O, Bernini A, Ciutti A, Chiellini S, Menciasci N, Finetti F, et al. Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. *Biochem Biophys Res Commun* 2003 Oct 10;310(1):78–83. [PubMed: 14511651]
76. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. *J Virol* 2003 Aug;77(16):8801–11. [PubMed: 12885899]
77. Li W, Moore MJ, Vasileva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 2003 Nov 27;426(6965):450–4. [PubMed: 14647384]

78. Wang P, Chen J, Zheng A, Nie Y, Shi X, Wang W, et al. Expression cloning of functional receptor used by SARS coronavirus. *Biochem Biophys Res Commun* 2004 Mar 5;315(2):439–44. [PubMed: 14766227]
79. Yi CE, Ba L, Zhang L, Ho DD, Chen Z. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. *J Virol* 2005 Sep;79(18):11638–46. [PubMed: 16140741]
80. Babcock GJ, Eshaki DJ, Thomas WD Jr, Ambrosino DM. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. *J Virol* 2004 May;78(9):4552–60. [PubMed: 15078936]
81. Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K, Dimitrov DS. The SARS-CoV S glycoprotein: expression and functional characterization. *Biochem Biophys Res Commun* 2003 Dec 26;312(4):1159–64. [PubMed: 14651994]
82. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. *Biochem Biophys Res Commun* 2004 Nov 12;324(2):773–81. [PubMed: 15474494]
83. Hua RH, Wang YF, Bu ZG, Zhou YJ, Ge JY, Wang XJ, et al. Identification and antigenic epitope mapping of immunodominant region amino residues 510 to 672 on the spike protein of the severe acute respiratory syndrome coronavirus. *DNA Cell Biol* 2005 Aug;24(8):503–9. [PubMed: 16101348]
84. Zhao J, Wang W, Wang GF, Li Y, Zhuang H, Xu X, et al. Development and evaluation of an enzyme-linked immunosorbent assay for detection of antibodies against the spike protein of SARS-coronavirus. *J Clin Virol* 2005 May;33(1):12–8. [PubMed: 15797360]
85. Zhou T, Wang H, Luo D, Rowe T, Wang Z, Hogan RJ, et al. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. *J Virol* 2004 Jul;78(13):7217–26. [PubMed: 15194798]
86. Lu L, Manopo I, Leung BP, Chng HH, Ling AE, Chee LL, et al. Immunological characterization of the spike protein of the severe acute respiratory syndrome coronavirus. *J Clin Microbiol* 2004 Apr;42(4):1570–6. [PubMed: 15071006]
87. Manopo I, Lu L, He Q, Chee LL, Chan SW, Kwang J. Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV. *J Immunol Methods* 2005 Jan;296(12):37–44. [PubMed: 15680149]
88. Zhou YJ, Hua RH, Wang YF, An TQ, Liu JX, Yang JY, et al. Development of monoclonal antibodies against SARS-CoV and identification of antigenic epitopes. *Sheng Wu Gong Cheng Xue Bao* 2005 Mar;21(2):211–5. [PubMed: 16013477]
89. Groneberg DA, Hilgenfeld R, Zabel P. Molecular mechanisms of severe acute respiratory syndrome (SARS). *Respir Res* 2005 Jan 20;6(1):8. [PubMed: 15661082]
90. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. *Science* 2003 Jun 13;300(5626):1763–7. [PubMed: 12746549]
91. Lee TW, Cherney MM, Huitema C, Liu J, James KE, Powers JC, et al. Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide. *J Mol Biol* 2005 Nov 11;353(5):1137–51. [PubMed: 16219322]
92. Burnouf T, Radosevich M. Treatment of severe acute respiratory syndrome with convalescent plasma. *Hong Kong Med J* 2003 Aug;9(4):309. [PubMed: 12904626]author reply 10
93. Brim TA, VanCott JL, Lunney JK, Saif LJ. Cellular immune responses of pigs after primary inoculation with porcine respiratory coronavirus or transmissible gastroenteritis virus and challenge with transmissible gastroenteritis virus. *Vet Immunol Immunopathol* 1995 Sep;48(12):35–54. [PubMed: 8533315]
94. Takamura K, Matsumoto Y, Shimizu Y. Field study of bovine coronavirus vaccine enriched with hemagglutinating antigen for winter dysentery in dairy cows. *Can J Vet Res* 2002 Oct;66(4):278–81. [PubMed: 12418784]
95. Xiong S, Wang YF, Zhang MY, Liu XJ, Zhang CH, Liu SS, et al. Immunogenicity of SARS inactivated vaccine in BALB/c mice. *Immunol Lett* 2004 Sep;95(2):139–43. [PubMed: 15388253]

96. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. *Proc Natl Acad Sci U S A* 2004 Apr 27;101(17):6641–6. [PubMed: 15096611]
97. Wang X, Schnitzlein WM, Tripathy DN, Girshick T, Khan MI. Construction and immunogenicity studies of recombinant fowl poxvirus containing the S1 gene of Massachusetts 41 strain of infectious bronchitis virus. *Avian Dis* 2002 Oct-Dec;46(4):831–8. [PubMed: 12495043]
98. Kim TW, Lee JH, Hung CF, Peng S, Roden R, Wang MC, et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. *J Virol* 2004 May;78(9):4638–45. [PubMed: 15078946]
99. Zhu MS, Pan Y, Chen HQ, Shen Y, Wang XC, Sun YJ, et al. Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. *Immunol Lett* 2004 Apr 15;92(3):237–43. [PubMed: 15081618]
100. Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. *Nature* 2004 Apr 1;428(6982):561–4. [PubMed: 15024391]
101. Huang J, Cao Y, Du J, Bu X, Ma R, Wu C. Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses. *Vaccine* 2007 Sep 28;25(3940):6981–91. [PubMed: 17709158]
102. Yu H, Jiang LF, Fang DY, Yan HJ, Zhou JJ, Zhou JM, et al. Selection of SARS-coronavirus-specific B cell epitopes by phage peptide library screening and evaluation of the immunological effect of epitope-based peptides on mice. *Virology* 2007 Mar 15;359(2):264–74. [PubMed: 17055022]
103. Yu M, Stevens V, Berry JD, Cramer G, McEachern J, Tu C, et al. Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal species. *J Immunol Methods* 2008 Feb 29;331(12):1–12. [PubMed: 18191140]
104. Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. *J Virol* 2004 Apr;78(7):3572–7. [PubMed: 15016880]
105. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. *Proc Natl Acad Sci U S A* 2004 Jun 29;101(26):9804–9. [PubMed: 15210961]
106. Keng CT, Zhang A, Shen S, Lip KM, Fielding BC, Tan TH, et al. Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. *J Virol* 2005 Mar;79(6):3289–96. [PubMed: 15731223]
107. Pogrebnyak N, Golovkin M, Andrianov V, Spitsin S, Smirnov Y, Eglolf R, et al. Severe acute respiratory syndrome (SARS) S protein production in plants: Development of recombinant vaccine. *Proc Natl Acad Sci U S A* 2005 Jun 21;102(25):9062–7. [PubMed: 15956182]
108. He Y, Zhou Y, Wu H, Luo B, Chen J, Li W, et al. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. *J Immunol* 2004 Sep 15;173(6):4050–7. [PubMed: 15356154]
109. Wang S, Chou TH, Sakhatskyy PV, Huang S, Lawrence JM, Cao H, et al. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. *J Virol* 2005 Feb;79(3):1906–10. [PubMed: 15650214]
110. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. *J Immunol* 2005 Apr 15;174(8):4908–15. [PubMed: 15814718]
111. Jiang S, He Y, Liu S. SARS vaccine development. *Emerg Infect Dis* 2005 Jul;11(7):1016–20. [PubMed: 16022774]
112. Zhang MY, Choudhry V, Xiao X, Dimitrov DS. Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS. *Curr Opin Mol Ther* 2005 Apr;7(2):151–6. [PubMed: 15844623]

113. Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. *Lancet* 2003 Dec 6;362(9399):1895–6. [PubMed: 14667748]
114. Jin H, Xiao C, Chen Z, Kang Y, Ma Y, Zhu K, et al. Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice. *Biochem Biophys Res Commun* 2005 Mar 25;328(4):979–86. [PubMed: 15707974]
115. See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CP, Hogan RJ, et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. *J Gen Virol* 2006 Mar;87(Pt 3):641–50. [PubMed: 16476986]
116. Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. *Vaccine* 2007 Apr 12;25(15):2832–8. [PubMed: 17092615]
117. Gai W, Zou W, Lei L, Luo J, Tu H, Zhang Y, et al. Effects of Different Immunization Protocols and Adjuvant on Antibody Responses to Inactivated SARS-CoV Vaccine. *Viral Immunol* 2008 Mar;21(1):27–37. [PubMed: 18355120]
118. Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S, et al. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. *Vaccine* 2008 Mar 20;26(13):1644–51. [PubMed: 18289745]
119. Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, et al. Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection. *J Immunol* 2008 Jan 15;180(2):948–56. [PubMed: 18178835]